NCT05132803

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

A Feasibility Trial to Assess Intratumoral Injection of TA-CIN With Anti-PD-1 Therapy for Recurrent HPV16-associated Cancers

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: Female
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with anti-PD-1 therapy.

Conditions

• Recurrent Human Papillomavirus Type 16 Associated Cancer

Interventions

Type	Name	Description
DRUG	HPV 16 TA-CIN	No dose escalation or reduction

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-01-18
• Completion: 2022-01-18
• First posted: 2021-11-24
• Last updated: 2022-12-01

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study